Mark N. Milton
Research Subjects
Mark N. Milton has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Beryl B. Cummings
Broad Institute of MIT and Harvard
2 shared publications - Ethan J. Weiss
UCSF
2 shared publications - Page R. Bouchard
Marea Therapeutics , South San Francisco, CA 94080
2 shared publications Vyas Ramanan
Marea Therapeutics , South San Francisco, CA 94080
2 shared publicationsAmitabh V. Nimonkar
Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA
1 shared publication- An Zhao
Regeneron Pharmaceuticals Inc., Tarrytown, USA
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (9)
Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly
Acromegaly is a rare disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma. Pegvisomant is the only approved GH receptor antagonist (GHRA) and is administered via daily subcutaneous injections, which limits real-world effectiveness. Here, we report the discovery and characterization of MAR002, a novel, half-life extended monoclonal antibody GHRA. MAR002 was identified by immunizing transgenic mice with the extracellular domain of human and cynomolgus monkey GH receptor (GHR) and engineered with Fc modifications to limit effector function and extend serum half-life. MAR002 was benchmarked against pegvisomant in biophysical assays, cellular signaling inhibition studies, and a head-to-head pharmacokinetic/pharmacodynamic study in cynomolgus monkeys. MAR002 exhibited higher binding affinity to GHR and >100-fold more potent inhibition of GH-induced GHR signaling than pegvisomant (human half-maximal inhibitory concentration [IC50] 1.05 nM vs 122 nM). Epitope binning demonstrated simultaneous binding of MAR002 and GH to GHR, consistent with an allosteric, noncompetitive mechanism; notably, MAR002 inhibitory activity was maintained at supraphysiological GH concentrations, whereas pegvisomant activity was competitively reduced. In cynomolgus monkeys, a single 10 mg/kg intravenous dose of MAR002 sustained ≥50% IGF-1 suppression for 36 days compared with 15 days for an equimolar pegvisomant dose, with comparable maximal lowering (∼80%). These findings support clinical evaluation of MAR002 as a next-generation long-acting GHRA for acromegaly, with potential for reduced dosing frequency and more consistent suppression of the GH–IGF-1 axis.
- 3 August 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (9)
Open AccessDevelopment and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly
Acromegaly is a rare disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma. Pegvisomant is the only approved GH receptor antagonist (GHRA) and is administered via daily subcutaneous injections, which limits real-world effectiveness. Here, we report the discovery and characterization of MAR002, a novel, half-life extended monoclonal antibody GHRA. MAR002 was identified by immunizing transgenic mice with the extracellular domain of human and cynomolgus monkey GH receptor (GHR) and engineered with Fc modifications to limit effector function and extend serum half-life. MAR002 was benchmarked against pegvisomant in biophysical assays, cellular signaling inhibition studies, and a head-to-head pharmacokinetic/pharmacodynamic study in cynomolgus monkeys. MAR002 exhibited higher binding affinity to GHR and >100-fold more potent inhibition of GH-induced GHR signaling than pegvisomant (human half-maximal inhibitory concentration [IC50] 1.05 nM vs 122 nM). Epitope binning demonstrated simultaneous binding of MAR002 and GH to GHR, consistent with an allosteric, noncompetitive mechanism; notably, MAR002 inhibitory activity was maintained at supraphysiological GH concentrations, whereas pegvisomant activity was competitively reduced. In cynomolgus monkeys, a single 10 mg/kg intravenous dose of MAR002 sustained ≥50% IGF-1 suppression for 36 days compared with 15 days for an equimolar pegvisomant dose, with comparable maximal lowering (∼80%). These findings support clinical evaluation of MAR002 as a next-generation long-acting GHRA for acromegaly, with potential for reduced dosing frequency and more consistent suppression of the GH–IGF-1 axis.
- 5 January 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 43
Assessment of Immune Responses Against AAV Encoded Transgene Products
The number of clinical investigations and approved applications of adeno-associated virus (AAV) based transgene product (TP) delivery has grown steadily. T
- 5 January 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 43
Assessment of Immune Responses Against AAV Encoded Transgene Products
The number of clinical investigations and approved applications of adeno-associated virus (AAV) based transgene product (TP) delivery has grown steadily. T
- Open Access
- 12 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 117, 105748
An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates
- 12 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 117, 105748
Open AccessAn ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates